Safety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studies

Table 2 Pooled risk ratios of solicited local symptoms

Comparison	Studies, n	Subjects, n	Pooled RR [95% CI]	Reference
Pain
2vHPV vaccine vs Hepatitis vaccine^a	5	15,471	1.80 [1.29, 2.51]	[34, 35, 37, 41, 47]
2vHPVvaccine vs Placebo	7	5315	1.34 [1.15, 1.57]	[27, 31, 33, 36, 40, 44, 47]
4vHPVvaccine vs Placebo	6	3474	1.17 [1.10, 1.24]	[26, 30, 32, 38, 46]
Redness
2vHPV vaccine vs Hepatitis vaccine^a	5	15,471	1.77 [1.55, 2.02]	[34, 35, 37, 41, 47]
2vHPV vaccine vs Placebo	6	3374	1.77 [1.52, 2.07]	[27, 31, 33, 36, 40, 47]
4vHPV vaccine vs Placebo	2	1055	1.47 [1.18, 1.82]	[26]
Swelling
2vHPV vaccine vs Hepatitis vaccine^a	5	15,471	2.57 [2.19, 3.02]	[34, 35, 37, 41, 47]
2vHPV vaccine vs Placebo	7	5315	2.27 [1.78, 2.91]	[27, 31, 33, 36, 40, 44, 47]
4vHPV vaccine vs Placebo	4	2403	1.83 [1.50, 2.22]	[26, 38, 46]

Abbreviations: HPV human papillomavirus, 2vHPV bivalent human papillomavirus, 4vHPV quadrivalent human papillomavirus, RR risk ratio, CI confidence interval
^aFour studies [34, 35, 37, 41] used hepatitis A and one study [47] used hepatitis B vaccine as control

ISSN: 2055-0294